UnitedHealth Group is the world's largest health insurance company by revenue (~$448B in FY2025). Founded in 1977 as United HealthCare Corporation in Minneapolis, MN, it grew through aggressive acquisition of managed care plans and built Optum into a vertically integrated health services powerhouse. UNH serves ~50 million members across commercial, Medicare, and Medicaid plans.

2025 Crisis Context: UNH entered a perfect storm in 2025. Medicare Advantage (MA) medical loss ratios surged to ~90%+ as post-COVID utilization normalized higher than expected — industry-wide but UNH had the largest MA exposure. Simultaneously, Medicaid redetermination created adverse selection as sicker members retained coverage. The CEO assassination (Brian Thompson, December 2024) added governance uncertainty. The Change Healthcare cyberattack (2024) caused ~$1.1B in costs. DOJ antitrust probe into Optum's vertical integration adds regulatory tail risk.

Recovery thesis: CMS set 2026 MA rate increase at +5.06% (strongest in years), which should allow margin recovery. Optum Health and Optum Rx continue growing. UNH has historically been the best-managed health insurer with consistent 20%+ ROE. The question is timing and magnitude of recovery.

Green = >10% above current price. Red = >10% below. Gold = within ±10%.

Log-linear trend fitted to full price history. ±1.5σ bands. Green shaded zone = bottom 25% of historical range — historically attractive entry.

Bear case: UNH is not recovering — it's structurally impaired. Medicare Advantage is a broken product at these pricing levels, and the DOJ antitrust review could force Optum divestiture (eliminating 30-40% of EV). A 90%+ MLR in MA is not a one-year aberration — CMS will continue ratcheting down reimbursement while utilization normalizes to a permanently higher level. The CEO assassination revealed governance brittleness. At $286, even "discounted" UNH still prices in full recovery that may not materialize. Bear price target: $175–220.

Bull case: UNH has been through crises before and emerged stronger. The 2026 CMS rate increase of +5.06% is the largest favorable rate move in years — management guided conservatively in 2025 Q4 and sandbag regularly. Optum is a crown jewel generating 25-30% IRR on physician group acquisitions. The business has a 50-year track record. At 15x forward earnings — a multi-year low — this is a generational entry point if recovery is real. The $90/share FCF-per-share potential on normalized results makes $600+ a credible bull target.

Our base case — Accumulate with patience: The recovery is real but slow. 2026 EPS of $18 (consensus) requires things to go right — and they probably will. CMS rates improve. Optum keeps growing. MA membership growth slows but unit economics recover. FCF should normalize to $20B+ by FY2027. At a normalized 18x P/E on $22 EPS = $396 fair value. Current price of $286 represents a 28% discount. The risk is asymmetric — downside is protected by the Optum floor (~$150/share of enterprise value alone), while upside is $350-450 on 12-18 month recovery.

Key watch items: (1) Q1 2026 MA MLR trajectory — any stabilization below 89% is bullish; (2) DOJ/Antitrust progress — monitor quarterly; (3) FY2026 guidance raise on earnings calls; (4) Andrew Witty (new CEO) strategic communication.